Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

astellas d.o.o.,ilica 1, zagreb - solifenacinsukcinat tamsulozinklorid - tableta s prilagođenim oslobađanjem - 6 mg/0,4 mg - urbroj: jedna tableta sadrži sloj sa 6 mg solifenacinsukcinata, što odgovara 4,5 mg slobodne baze solifenacina, i sloj s 0,4 mg tamsulozinklorida, što odgovara 0,37 mg slobodne baze tamsulozina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fidifarm d.o.o., bestovje - in vitro dijagnostika-brzi test za upotrebu kod kuće za rano otkrivanje prostata specifičnog antigena psa u kapilarnoj krvi

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - apalutamide - prostatske neoplazme - endokrinska terapija - erleada drugačije:kod odraslih muškaraca u liječenju ne metastatic кастраци-uporan je rak prostate (nmcrpc), koje imaju visok rizik za razvoj bolesti метастатической. kod odraslih muškaraca u liječenju метастатического hormonski-senzitivni rak prostate (mhspc) u kombinaciji s terapijom oduzimanja андрогена (adt).

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - dutasterid - kapsula, meka - 0,5 mg/1 kapsula - 1 kapsula, meka sadrži: 0,5 mg dutasterida

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alkaloid d.o.o. sarajevo - dutasterid - kapsula, meka - 0,5 mg/1 kapsula - 1 kapsula, meka sadrži: 0,5 mg dutasterida

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatske neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - dutasterid - kapsula, meka - 0,5 mg/1 kapsula - 1 kapsula, meka sadrži: 0,5 mg dutasterida

Europska Unija - hrvatski - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatske neoplazme - endokrinska terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.